Evidence map›Paper›PMID 28079110›Full record

ReviewNature reviews. Cardiology2017

Left ventricular noncompaction cardiomyopathy: cardiac, neuromuscular, and genetic factors.

Josef Finsterer, Claudia Stöllberger, Jeffrey A Towbin

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Cardiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 100 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
100citing papers in PubMed, 2 pooled it
18.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

100 citing papers in PubMed, 2 syntheses or guidelines pooled it, 203 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Trial
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Deletion ofJournal of developmental biology · 2025
    Article
  15. Article
  16. Observational
  17. Left Ventricular Non-Compaction: Evolving Concepts.Journal of clinical medicine · 2024
    Review
  18. Article
  19. Article
  20. Review

40 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Josef FinstererKrankenanstalt Rudolfstiftung, Postfach 20, 1180 Vienna, Austria.
Claudia StöllbergerSecond Medical Department with Cardiology and Intensive Care Medicine, Krankenanstalt Rudolfstiftung, Juchgasse 25, 1030 Vienna, Austria.
Jeffrey A TowbinThe Heart Institute, Le Bonheur Children's Hospital, University of Tennessee Health Science Center, and St. Jude Children's Research Hospital, 51 N Dunlap Street #100, Memphis, Tennessee 38105, USA.
Krankenanstalt Rudolfstiftung der Stadt Wien · ATLe Bonheur Children's Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Left ventricular hypertrabeculation (LVHT) or noncompaction is a myocardial abnormality of unknown aetiology, frequently associated with monogenic disorders, particularly neuromuscular disorders, or with chromosomal defects. LVHT is diagnosed usually by echocardiography by the presence of a bilayered myocardium consisting of a thick, spongy, noncompacted endocardial layer and a thin, compacted, epicardial layer. The pathogenesis of LVHT is unsolved, and the diagnostic criteria, prognosis, and optimal treatment of patients with LVHT are under debate. LVHT is categorized as distinct primary genetic cardiomyopathy by the AHA and as unclassified cardiomyopathy by the ESC. LVHT is usually asymptomatic, but can be complicated by heart failure, thromboembolism, or ventricular arrhythmias, including sudden cardiac death. Mortality of patients with LVHT ranges from 5% to 47%. Anticoagulation is indicated if atrial fibrillation, severe heart failure, previous embolism, or intracardiac thrombus formation are present. In patients with LVHT with late gadolinium enhancement, an implantable cardioverter-defibrillator might be considered if systolic dysfunction, a family history of sudden cardiac death, nonsustained ventricular tachycardia, or previous syncope is additionally present. In this Review, we discuss the current findings on the aetiology and pathophysiology of LVHT, and provide an overview of the diagnosis, available treatment, and prognosis of this cardiomyopathy.

Indexed as

Heart Defects, CongenitalDeath, Sudden, CardiacDisease ManagementGenetic Predisposition to DiseaseHumansPrognosis

Identifiers

PMID28079110
OpenAlexW2577523630

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.